T89 Drug Clinical Studies
Prescription Drug Clinical Studies
Dantonic® is a modernized and industrialized botanical drug formula of Danshen (Radix Salviae Miltiorrhizae, RSM) and Sanqi (Radix Notoginseng, RN) as active ingredients and Borneol as absorption enhancer. Dantonic® was approved as a prescription drug for the treatment of chronic stable angina pectoris in patients with coronary heart disease by the State Food and Drug Administration of China (CFDA) in 1993.
Dantonic® is currently approved in 24 countries (not in the USA yet) for the treatment and prevention of chronic stable angina pectoris and other cardiovascular disease related conditions. More than 2 billion doses have been prescribed worldwide. It is coded as T89 in the US development. T89 has been studied in well controlled US and global clinical trial.
T89 Phase I study (Dose escalating studies)
Phase I studies were carried out in China, Australia and Japan. The studies showed that T89 has a very good safety profile.